Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
10/21/2013 9:18:44 AM
NEW YORK and LONDON, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company's MRX-6 treatment for eczema has been selected as one of the "Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information. Celsus management will present the project to a select group of pharmaceutical company executives at Windhover's Therapeutic Area Partnerships meeting in Boston, November 18-20.
Help employers find you! Check out all the jobs and post your resume.